Capivasertib

• Description :

  Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1, Akt2 and Akt3, respectively.

• CAS Number :

  [1143532-39-1]

• Product Name Alternative :

  AZD5363

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Akt; Autophagy

• Type :

  Reference compound

• Related Pathways :

  Autophagy; PI3K/Akt/mTOR

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/AZD5363.html

• Purity :

  99.96

• Solubility :

  DMSO : 125 mg/mL (ultrasonic)

• Smiles :

  O=C(C1(N)CCN(C2=C3C(NC=C3)=NC=N2)CC1)N[C@H](C4=CC=C(Cl)C=C4)CCO

• Molecular Formula :

  C21H25ClN6O2

• Molecular Weight :

  428.92

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Davies BR, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11 (4) :873-87.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  Akt1; Akt2; Akt3